Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02729714 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
A Phase 4 study of Insomnia, sponsored by Burdick, Daniel, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02729714 is a Phase 4 study of Insomnia that has completed, run by Burdick, Daniel, M.D.. The registered enrollment target is 21 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02729714, a Phase 4 study of Insomnia, has completed, sponsored by Burdick, Daniel, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the study drug, suvorexant, is safe and effective in treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of insomnia will participate in the study at this site
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Suvorexant
Study Locations (1)
Washington
- Evergreenhealth Booth Gardner Parkinsons Care Center - Kirkland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-04 |
| Est. Completion | 2022-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02729714
The ClinicalTrials.gov registry entry for NCT02729714 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (88% lower). The listed sponsor is Burdick, Daniel, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02729714 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT02729714 about?
NCT02729714 is a clinical study titled "A Pilot Study of Suvorexant for Insomnia in Parkinson Disease". The purpose of this study is to see if the study drug, suvorexant, is safe and effective in treating symptoms of insomnia in people with Parkinson's Disease. It is anticipated that a total of 20 subjects, 30 to 80 years of age, with Parkinson's Disease and symptoms of insomnia will participate in th...
What is the current status of trial NCT02729714?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2016-04. Estimated completion is 2022-04.
What conditions does trial NCT02729714 study?
This clinical trial studies the following conditions: Insomnia.
What interventions are being tested in trial NCT02729714?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT02729714?
This trial is sponsored by Burdick, Daniel, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02729714 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms
RECRUITING · Phase 4
-
Enhancing Hypnotic Medication Discontinuation in Primary Care
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial
ACTIVE NOT RECRUITING · Phase 4
-
Solriamfetol and CBT-I in Patients With Insomnia Disorder
ACTIVE NOT RECRUITING · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.